Equity Profile

LEGN

Legend Biotech Corporation

Health CareBiotechnology$5.0B

Dec1Thu

Pre-Earnings Brief

UpcomingQ2-2024After Close5:00 PM EST

Company Snapshot

Legend Biotech Corporation is a biotechnology company focused on developing innovative cell therapies for cancer treatment. As part of the health care sector, its advancements in biopharmaceuticals are crucial for addressing unmet medical needs in oncology.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its therapies.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

LEGN Q2-2024 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 6Q

EPS Beat Streak

EPS Beat Rate

67%

Avg EPS Surprise

+12.73%

Avg Stock Reaction

+3.44%

Last Quarter Recap

In the last quarter, Legend Biotech reported an EPS of -$0.16, which was better than the expected -$0.29, indicating a positive surprise. However, there was no revenue reported, leaving investors uncertain about overall sales performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Legend Biotech's upcoming earnings report, especially after the positive EPS surprise last quarter. However, the lack of revenue guidance raises concerns about the sustainability of this performance.

Bull Case

If Legend Biotech can continue to beat EPS estimates and show signs of revenue growth, it may signal strong demand for its therapies and boost investor confidence.

Bear Case

Conversely, if the company fails to provide any revenue figures or guidance, it could lead to skepticism about its growth prospects and result in a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific revenue figures can Legend Biotech provide for its therapies this quarter?

Revenue figures are critical for assessing the company's market performance and growth potential, especially after the previous quarter's lack of data.

Will there be any updates on the progress of ongoing clinical trials?

Updates on clinical trials can significantly impact investor sentiment and provide insights into future revenue potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Legend Biotech's therapies to gain traction in the market, especially given the recent positive EPS surprise.

Supporting Evidence

The options market is pricing a significant move, indicating that traders expect volatility, which may reflect underlying confidence.

The company's history of beating EPS estimates suggests that it may have the capacity to surprise positively again.

Key Risk

If Legend Biotech can demonstrate strong revenue growth or provide promising updates on clinical trials, it could challenge the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for growth against the uncertainty of revenue generation, making this quarter pivotal for Legend Biotech.

Bull Confirmed If

A revenue figure that exceeds expectations would confirm strong market demand for Legend Biotech's therapies.

Bear Confirmed If

Failure to provide any revenue guidance or a significant miss on EPS could lead to a bearish outlook.

Pre-Earnings Positioning

Options Market

Implied Move

±14.82%

Historical Avg

±6.1%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±14.8% while LEGN has averaged ±6.1% over the last 6 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

85.1%

Calls (20K)P/C Ratio: 0.10Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Legend Biotech beats expectations and raises guidance, history suggests a positive reaction, with an average 1-day move of +1.71%.

In-Line / Cautious

If results are in line but lack strong guidance, the stock may see muted movement as investors reassess their outlook.

Miss

A miss on EPS or revenue could lead to a negative reaction, with history suggesting an average 1-day move of +6.91% when they miss.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific revenue figures for the quarter.
2Updates on ongoing clinical trials and their timelines.
3Management's outlook on market demand for their therapies.
4Comments on competitive positioning within the biotechnology sector.
5Insights into potential partnerships or collaborations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Elbit Systems Ltd.

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its therapies.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

LEGN Q2-2024 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 6Q

EPS Beat Streak

EPS Beat Rate

67%

Avg EPS Surprise

+12.73%

Avg Stock Reaction

+3.44%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Legend Biotech can continue to beat EPS estimates and show signs of revenue growth, it may signal strong demand for its therapies and boost investor confidence.

Bear Case

Conversely, if the company fails to provide any revenue figures or guidance, it could lead to skepticism about its growth prospects and result in a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific revenue figures can Legend Biotech provide for its therapies this quarter?

Revenue figures are critical for assessing the company's market performance and growth potential, especially after the previous quarter's lack of data.

Will there be any updates on the progress of ongoing clinical trials?

Updates on clinical trials can significantly impact investor sentiment and provide insights into future revenue potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Legend Biotech's therapies to gain traction in the market, especially given the recent positive EPS surprise.

Supporting Evidence

The options market is pricing a significant move, indicating that traders expect volatility, which may reflect underlying confidence.

The company's history of beating EPS estimates suggests that it may have the capacity to surprise positively again.

Key Risk

If Legend Biotech can demonstrate strong revenue growth or provide promising updates on clinical trials, it could challenge the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for growth against the uncertainty of revenue generation, making this quarter pivotal for Legend Biotech.

Bull Confirmed If

A revenue figure that exceeds expectations would confirm strong market demand for Legend Biotech's therapies.

Bear Confirmed If

Failure to provide any revenue guidance or a significant miss on EPS could lead to a bearish outlook.

Pre-Earnings Positioning

Options Market

Implied Move

±14.82%

Historical Avg

±6.1%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±14.8% while LEGN has averaged ±6.1% over the last 6 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

85.1%

Calls (20K)P/C Ratio: 0.10Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Legend Biotech beats expectations and raises guidance, history suggests a positive reaction, with an average 1-day move of +1.71%.

In-Line / Cautious

If results are in line but lack strong guidance, the stock may see muted movement as investors reassess their outlook.

Miss

A miss on EPS or revenue could lead to a negative reaction, with history suggesting an average 1-day move of +6.91% when they miss.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific revenue figures for the quarter.
2Updates on ongoing clinical trials and their timelines.
3Management's outlook on market demand for their therapies.
4Comments on competitive positioning within the biotechnology sector.
5Insights into potential partnerships or collaborations.